Nurix Therapeutics (NRIX) announced that the U.S. Food and Drug Administration has granted Fast Track designation for NX-5948, a highly selective degrader of Bruton’s tyrosine kinase, BTK, for the treatment of adult patients with relapsed or refractory Waldenstrom’s macroglobulinemia after at least two lines of therapy, including a BTK inhibitor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target raised to $35 from $30 at H.C. Wainwright
- Nurix Therapeutics initiated with a Buy at BTIG
- Nurix Therapeutics Reports Promising Trial Results for NX-5948
- Nurix Therapeutics holds a pharmaceutical update conference call
- Nurix Therapeutics initiated with an Outperform at BMO Capital
Questions or Comments about the article? Write to editor@tipranks.com